TMCI
Treace Reports Q2 2026 Revenue Decrease and Adjusted EBITDA Loss
Treace Medical Concepts reported a 4% decline in second-quarter 2026 revenue to $45.4 million, demonstrating a reduction in sequential year-over-year growth. This was accompanied by a higher net loss per share despite year-to-date cash usage dropping by 57%, indicating improved liquidity management.